Health insurance company Oscar Health (NYSE: OSCR) beat Wall Street’s revenue expectations in Q3 2026, with sales up 72.1% year on year to $5.14 billion. The company’s full-year revenue guidance of $19.15 billion at the midpoint came in 2.2% above analysts’ estimates. Its non-GAAP profit of $0.49 per share was significantly above analysts’ consensus estimates.

Is now the time to buy OSCR? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Oscar Health posted results above Wall Street’s expectations in the third quarter, but the market reaction was negative, reflecting investor caution around the sustainability of recent gains. Management attributed the quarter’s performance to disciplined pricing, AI-driven operational efficiencies, and favorable risk adjustment data. CEO Mark Bertolini emphasized that Oscar’s medical loss ratio improved due to a shift from inpatient to outpatient care, underpinned by affordability initiatives and ongoing cost management. Management also noted that administrative expenses reached a company low, supported by technology investments.

Looking forward, Oscar Health’s guidance is influenced by expectations of stable marketplace membership, new product launches, and pricing actions targeting higher medical costs and market morbidity. Management is focused on margin expansion and market share gains through a combination of technology-driven support and expanded distribution. CFO Scott Blackley highlighted that risk adjustment and utilization trends remain key variables, while CEO Mark Bertolini pointed to new offerings like RetireEase and bundled benefits as avenues for growth. The company expects ongoing program integrity efforts and competitive pricing dynamics to shape results in the coming year.

Key insights from management’s remarks

Oscar Health’s management credited strong third quarter results to pricing strategy, risk adjustment gains, and technology-enabled cost controls. The company’s evolving product portfolio and market expansion also contributed to performance, while ongoing regulatory changes and competitor exits shaped the operating environment.

• AI-powered cost controls: Management pointed to technology and artificial intelligence initiatives as critical in reducing administrative costs, with the SG&A expense ratio hitting a record low of 14%. These efficiencies enabled greater fixed cost leverage and operational discipline.
• Risk adjustment boost: CFO Scott Blackley highlighted that updated risk adjustment data provided a $250 million revenue benefit in the quarter, reflecting Oscar’s improved risk profile relative to the market. Management noted that not all of this benefit falls to the bottom line, as some is offset by higher claims costs.
• Shift to outpatient care: Management observed a rotation from inpatient to outpatient services, partially driven by affordability initiatives. This trend supported a favorable medical loss ratio and aligns with efforts to make care more cost-effective for members.
• Market expansion and new products: Oscar grew its membership base by 27% year-over-year and expanded its footprint to 713 counties across 21 states, including entry into South Carolina. The introduction of new offerings like RetireEase for early retirees and bundled dental/vision plans targeted high-value, underserved consumer segments.
• Competitive landscape shaped by exits: The company is capitalizing on approximately 850,000 individuals entering the market due to competitor withdrawals, helping offset headwinds from ongoing CMS eligibility reviews and supporting share gains in targeted markets.

Drivers of future performance

Oscar Health’s outlook centers on disciplined pricing, new product adoption, and technology-driven efficiency gains amid ongoing regulatory and market changes.

• Pricing actions and medical cost trends: Management expects a weighted average rate increase of about 14% for the next enrollment cycle, driven primarily by elevated medical cost trends and higher market morbidity. CEO Mark Bertolini emphasized that careful rate setting, combined with ongoing cost controls, is vital to maintaining profitability as the market stabilizes.
• Program integrity and membership stability: Regulatory initiatives to verify member eligibility—such as CMS’s program integrity efforts—are expected to continue, with management building these dynamics into their guidance. Although these measures may suppress overall market growth, Oscar anticipates stable membership and sees potential for share gains as it expands into new markets and segments.
• Product innovation and distribution: Management is counting on new products like RetireEase and expanded partnerships (e.g., Allstate Health Solutions) to drive incremental growth. Technology platforms such as Lucie are designed to streamline plan selection and broker productivity, which management believes will enhance Oscar’s competitive position even as pricing competition intensifies.

Catalysts in upcoming quarters

For the next few quarters, the StockStory team will be monitoring (1) the effectiveness of Oscar’s new product launches, especially RetireEase and supplemental benefit offerings, (2) the market response to expanded geographic coverage and the impact of competitor exits on member growth, and (3) progress in driving down administrative costs through AI and technology investments. We will also watch for how regulatory changes and further CMS eligibility reviews influence risk adjustment, membership stability, and profitability.

Oscar Health currently trades at $33, down from $35.19 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

Now could be the perfect time to invest in these stocks

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.